Stay updated on Resmetirom Safety and Biomarkers Clinical Trial
Sign up to get notified when there's something new on the Resmetirom Safety and Biomarkers Clinical Trial page.

Latest updates to the Resmetirom Safety and Biomarkers Clinical Trial page
- CheckyesterdayChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe MAESTRO-NAFLD-1 trial page now displays a 403 Forbidden error, replacing the full study record and its details with an access block. Users cannot view the trial's title, identifiers, conditions, locations, or dates.SummaryDifference18%

- Check42 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, indicating a newer build of the page.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page now shows a new revision label (v3.6.5) replacing the previous v3.6.4, indicating a deployment-level update to the page.SummaryDifference0.0%

- Check79 days agoChange DetectedUpdated the document revision tag from v3.6.3 to v3.6.4, signaling a newer revision of the page rather than a substantive content change.SummaryDifference0.0%

- Check86 days agoChange DetectedSteatotic Liver Disease was added to the list of related terms on the page, and Fatty Liver Disease was removed. This updates the page's terminology to reflect current disease nomenclature and enhances clarity for readers and indexing.SummaryDifference0.0%

Stay in the know with updates to Resmetirom Safety and Biomarkers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom Safety and Biomarkers Clinical Trial page.